Glofitamab is a T-cell–engaging bispecific antibody that targets CD3 and CD20, demonstrating significant antitumor activity and durable responses in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). It works by binding to CD20 on B cells and CD3 on T cells, promoting T-cell-mediated lysis of malignant B cells. MW: 170.28 KD.